

# TABLE OF CONTENTS

|   |           |
|---|-----------|
| <b>GLOSSARY .....</b>   | <b>3</b>  |
| <b>RESUME .....</b>   | <b>7</b>  |
| <b>ABSTRACT .....</b>   | <b>9</b>  |
| <b>LIST OF FIGURES .....</b>  | <b>10</b> |
| <b>LIST OF TABLES.....</b>  | <b>13</b> |
| <b>1. INTRODUCTION .....</b>  | <b>14</b> |
| 1.1 AORTIC VALVE.....   | 14        |
| 1.1.1 <i>Anatomy structure and function</i> .....   | 14        |
| 1.1.2 <i>Aortic valve regurgitation</i> .....   | 15        |
| 1.1.2.1 Definition .....  | 15        |
| 1.1.2.2 Epidemiology .....  | 16        |
| 1.1.2.3 Etiology .....  | 17        |
| 1.1.2.4 Pathophysiology.....  | 18        |
| 1.1.2.5 Natural history and treatments .....  | 20        |
| 1.1.2.6 Treatments.....   | 21        |
| 1.2 EXPERIMENTAL AORTIC REGURGITATION .....   | 23        |
| 1.3 OMECAMTIV MECARBIL.....   | 25        |
| 1.3.1 <i>Background</i> .....   | 25        |
| 1.3.2 <i>Pharmacodynamics and pharmacokinetics</i> .....  | 28        |
| 1.3.3 <i>Bioenergetic aspects</i> .....   | 30        |
| 1.3.4 <i>Clinical efficacy</i> .....  | 31        |
| 1.4 CARDIAC BIOMARKERS .....  | 33        |
| 1.4.1 <i>N-terminal pro-B-type natriuretic peptide (NT-proBNP)</i> .....  | 33        |
| 1.4.2 <i>Soluble suppression of tumorigenicity 2 (also called interleukin 1 receptor-like 1; sST2)</i> .....                        | 33        |
| 1.5 LEFT VENTRICULAR GENE EXPRESSION PROFILE .....  | 35        |
| 1.5.1 <i>Apoptosis and oxidative stress determinants</i> .....  | 35        |
| 1.5.1.1 Mitochondrial members Bax and Bcl-2.....  | 35        |
| 1.5.1.2 Biomarkers of oxidative stress .....  | 35        |
| 1.5.2 <i>Molecules implicated in energy substrate use</i> .....   | 36        |
| 1.5.2.1 AMPK, PPAR $\alpha$ , and PPAR $\gamma$ .....   | 36        |
| 1.5.2.2 Glucose transporters Glut1 and Glut4 .....  | 37        |
| 1.5.2.3 PDK4 and CPT1.....  | 38        |
| 1.5.2.4 CD36, Lox 1, and ALOX15 .....   | 39        |
| 1.5.3 <i>Vasoactive determinants</i> .....  | 40        |
| 1.5.3.1 Angiotensin receptors AT1 and AT2.....  | 40        |
| 1.5.3.2 ACE1 and ACE2.....  | 41        |
| 1.5.3.3 eNOS and iNOS .....   | 41        |
| 1.5.3.4 Kallikrein-kinin signalling.....  | 42        |
| 1.5.3.5 Bradykinin receptors.....   | 43        |
| 1.5.3.6 Calcium-dependent myocardial contraction.....   | 44        |
| <b>2. GENERAL HYPOTHESIS AND AIMS OF THE RESEARCH WORK .....</b>  | <b>46</b> |
| <b>3. METHODS.....</b>  | <b>49</b> |
| 3.1 EFFECTS OF OMECAMTIV MECARBIL ON CARDIAC FUNCTION, AORTIC REGURGITATION AND LV WALL STRESS IN AN EXPERIMENTAL RAT'S MODEL ..... | 49        |
| 3.1.1 <i>Experimental animals</i> .....   | 49        |

|  |            |
|--|------------|
| 3.1.2 Anesthesia and surgical procedure.....   | 50         |
| 3.1.3 Cardiac measurements.....  | 50         |
| 3.1.4 Calculation of wall stress variables.....  | 52         |
| 3.1.5 Invasive blood pressure measurement.....   | 52         |
| 3.1.6 Experimental design.....   | 53         |
| 3.1.7 Statistical analyses.....  | 53         |
| 3.2 EFFECTS OF OMECAMTIV MECARBIL AND AORTIC REGURGITATION ON CARDIAC BIOMARKERS IN AN EXPERIMENTAL RAT MODEL..... | 54         |
| 3.2.1 Study protocol.....  | 54         |
| 3.2.2 Study Design.....  | 54         |
| 3.2.3 Measurements of plasma levels of sST2 and NT-proBNP.....   | 55         |
| 3.2.4 Statistical analysis.....  | 56         |
| 3.3 EFFECTS OF OMECAMTIV MECARBIL AND AORTIC REGURGITATION ON LEFT VENTRICLE IN AN EXPERIMENTAL RAT'S MODEL.....   | 56         |
| 3.3.1 Protocol and experimental design.....  | 57         |
| 3.3.2 Real-time quantitative polymerase chain reaction (RTq-PCR).....  | 57         |
| 3.3.3 Statistical analysis.....  | 63         |
| <b>4. RESULTS.....</b>   | <b>64</b>  |
| 4.1 EFFECTS OF AR ON RATS LEFT VENTRICLE, CARDIAC BIOMARKERS AND LV GENES EXPRESSION.....                          | 64         |
| 4.1.1 AR and LV measurements.....  | 64         |
| 4.1.2 AR effects on wall stress and blood pressure.....  | 67         |
| 4.1.3 Effects of AR on cardiac biomarkers.....   | 67         |
| 4.1.3.1 Plasma NT-proBNP levels in rats with AR.....   | 67         |
| 4.1.3.2 Plasma sST2 levels in rats with AR.....  | 68         |
| 4.1.4 Effects of AR in rats LV genes expression.....   | 71         |
| 4.1.4.1 AR and LV expression of genes regulating apoptosis and oxidative stress.....                               | 71         |
| 4.1.4.2 AR impacted LV expression profile of key determinants of cardiac energy substrate use.....                 | 73         |
| 4.1.4.3 AR altered LV expression of genes implicated in cardiac contractility.....                                 | 75         |
| 4.2 EFFECTS OF OM AND PLACEBO ON LV RATS WITH AR.....  | 76         |
| 4.2.1 Effects of placebo in rats with AR.....  | 76         |
| 4.2.2 Effects of OM rat with AR.....   | 79         |
| 4.2.3 Effects of OM compared with placebo rats with AR.....  | 80         |
| 4.2.4 effects of OM in sham-operated rats.....   | 84         |
| 4.3 EFFECTS OF OM AND PLACEBO ON CARDIAC BIOMARKERS.....   | 85         |
| 4.3.1 Effects of OM and placebo on plasma NT-proBNP levels.....  | 85         |
| 4.3.2 Effects of OM and placebo on plasma sST2 levels.....   | 86         |
| 4.4 OM AND LV GENES EXPRESSION.....  | 87         |
| 4.4.1 OM and LV Expression of Genes Regulating Apoptosis and Oxidative Stress.....                                 | 87         |
| 4.4.2 OM and LV Expression of genes determinants of Cardiac Energy Substrate Use.....                              | 88         |
| 4.4.3 OM and LV Expression of Genes Implicated in Cardiac Contractility.....                                       | 91         |
| <b>5. GENERAL DISCUSSION.....</b>  | <b>93</b>  |
| 5.1 EFFECT OF AR ON CARDIAC FUNCTION.....  | 93         |
| 5.2 EFFECT OF OM ON AR AND WALL STRESS.....  | 95         |
| 5.3 EFFECT OF OM ON CARDIAC FUNCTION.....  | 96         |
| 5.4 THE DIFFERENTIAL RESPONSE OF CARDIO BIOMARKERS TO OM IN EXPERIMENTAL MODEL OF AR.....                          | 99         |
| 5.5 OM AND LV RAT'S GENE EXPRESSION.....   | 102        |
| 5.6 COMBINED VOLUME AND PRESSURE OVERLOAD AND LV RAT'S GENE EXPRESSION.....  | 107        |
| 5.7 LIMITATIONS OF THE STUDIES AND PERSPECTIVES.....   | 110        |
| <b>6. CONCLUSION.....</b>  | <b>111</b> |

|                                   |            |
|-----------------------------------|------------|
| <b>7. REFERENCES .....</b>        | <b>112</b> |
| <b>8. APPENDIX A.....</b>         | <b>142</b> |
| .....                             | 143        |
| .....                             | 145        |
| .....                             | 146        |
| <b>9. APPENDIX B.....</b>         | <b>151</b> |
| .....                             | 152        |
| .....                             | 153        |
| .....                             | 154        |
| .....                             | 155        |
| .....                             | 156        |
| .....                             | 157        |
| <b>10. APPENDIX C.....</b>        | <b>161</b> |
| .....                             | 162        |
| .....                             | 164        |
| .....                             | 166        |
| .....                             | 167        |
| <b>11. APPENDIX D.....</b>        | <b>169</b> |
| .....                             | 171        |
| .....                             | 173        |
| .....                             | 174        |
| .....                             | 177        |
| .....                             | 179        |
| .....                             | 180        |
| .....                             | 181        |
| <b>12. APPENDIX E.....</b>        | <b>184</b> |
| <b>LIST OF PUBLICATIONS .....</b> | <b>209</b> |